A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to assess preliminary efficacy, determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.

Trial Details

NCT ID
NCT07086105
Phase
PHASE1
Sponsor
Adze Biotechnology Australia Pty Ltd
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Adze1.C
Locations (sample)
  • Southport, Queensland, Australia|-27.96724,153.39796
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Clayton, Victoria, Australia|-37.91667,145.11667

Key Eligibility Criteria

  • Male or female participants aged 18 years or older at Screening.
  • Histologically confirmed unresectable Stage IIIB to IV metastatic melanoma.
  • Refractory to, or unsuitable for, standard treatment options as determined by the investigator.
  • Not a suitable candidate for curative resection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →